Feng Xiaomeng, Gao Xia, Jia Yumei, Zhang Heng, Xu Yuan, Wang Guang
Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China (mainland).
Med Sci Monit. 2016 Mar 5;22:743-51. doi: 10.12659/msm.897307.
BACKGROUND Regulated upon activation, normal T cells expressed and secreted (RANTES) is associated with inflammation and atherosclerosis. We investigated the effect of fenofibrate, a peroxisome proliferator-activated receptor-α (PPAR-α) agonist, on RANTES in type 2 diabetes mellitus (T2DM) patients with hypertriglyceridemia. MATERIAL AND METHODS This study evaluated cross-sectional and interventional studies of 25 T2DM patients with hypertriglyceridemia (group A) and 32 controls (group B). Group A was treated with fenofibrate (200 mg/day) for 8 weeks. Serum RANTES and clinical characteristics were examined. RESULTS Serum RANTES was significantly higher in group A compared with group B (59.04±16.74 vs. 38.57±12.98 ng/ml, P<0.001) and correlated with triglycerides (TG) (r=0.535, P<0.001), fasting blood glucose (FBG) (r=0.485, P<0.001), glycosylated hemoglobin (HbA1c) (r=0.485, P<0.001), homocysteine (Hcy) (r=0.520, P<0.001), and high-sensitivity C-reactive protein (hsCRP) (r=0.701, P<0.001). In multiple regression analysis after controlling for confounders, increased hsCRP levels (β=7.430, P<0.001) and T2DM with hypertriglyceridemia (β=11.496, P=0.002) were independently related to high serum RANTES levels. After 8 weeks of fenofibrate treatment, serum RANTES significantly decreased in group A compared with baseline (52.75±17.41 vs. 59.04±16.74 ng/ml, P=0.018). CONCLUSIONS Fenofibrate decreased serum RANTES levels in T2DM patients with hypertriglyceridemia, indicating that PPAR-a agonists may play an important role in inhibiting inflammatory responses.
背景 活化后正常T细胞表达和分泌因子（RANTES）与炎症和动脉粥样硬化相关。我们研究了过氧化物酶体增殖物激活受体-α（PPAR-α）激动剂非诺贝特对2型糖尿病（T2DM）合并高甘油三酯血症患者RANTES的影响。材料与方法 本研究评估了25例T2DM合并高甘油三酯血症患者（A组）和32例对照者（B组）的横断面研究和干预性研究。A组接受非诺贝特（200mg/天）治疗8周。检测血清RANTES和临床特征。结果 A组血清RANTES显著高于B组（59.04±16.74 vs. 38.57±12.98ng/ml，P<0.001），且与甘油三酯（TG）（r=0.535，P<0.001）、空腹血糖（FBG）（r=0.485，P<0.001）、糖化血红蛋白（HbA1c）（r=0.485，P<0.001）、同型半胱氨酸（Hcy）（r=0.520，P<0.001）及高敏C反应蛋白（hsCRP）（r=0.701，P<0.001）相关。在控制混杂因素后的多元回归分析中，hsCRP水平升高（β=7.430，P<0.001）及T2DM合并高甘油三酯血症（β=11.496，P=0.002）与血清RANTES高水平独立相关。非诺贝特治疗8周后，A组血清RANTES较基线显著降低（52.75±17.41 vs. 59.04±16.74ng/ml，P=0.018）。结论 非诺贝特降低了T2DM合并高甘油三酯血症患者的血清RANTES水平，表明PPAR-α激动剂可能在抑制炎症反应中起重要作用。
